Cargando…
Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment
Transforming growth factor‐β (TGF‐β) and programmed death ligand 1 (PD‐L1) initiate signaling pathways with complementary, nonredundant immunosuppressive functions in the tumor microenvironment (TME). In the TME, dysregulated TGF‐β signaling suppresses antitumor immunity and promotes cancer fibrosis...
Autores principales: | Gulley, James L., Schlom, Jeffrey, Barcellos‐Hoff, Mary Helen, Wang, Xiao‐Jing, Seoane, Joan, Audhuy, Francois, Lan, Yan, Dussault, Isabelle, Moustakas, Aristidis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168966/ https://www.ncbi.nlm.nih.gov/pubmed/34854206 http://dx.doi.org/10.1002/1878-0261.13146 |
Ejemplares similares
-
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
por: Lind, Hanne, et al.
Publicado: (2020) -
TGF-β Signaling
por: Tzavlaki, Kalliopi, et al.
Publicado: (2020) -
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021) -
Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
por: Jochems, Caroline, et al.
Publicado: (2017) -
Long non‐coding RNAs and TGF‐β signaling in cancer
por: Papoutsoglou, Panagiotis, et al.
Publicado: (2020)